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Abstract
Purpose The last two decades witnessed the development
of numerous innovative regimens for the management of
patients with abnormally healing and infected wounds.
Growth factors, negative pressure wound therapy (NPWT)
and antiseptic dressings containing silver are examples of
methods with best documented efficacy, being widely used
in the treatment of acute and chronic post-traumatic
wounds, burns and ulcers of various etiology. As far as
obstetrics and gynecology are concerned, prevention and
treatment of infected, hard-to-heal postoperative wounds is
of crucial importance. This article reviews the available
literature to discuss the possibilities for use, efficacy and
cost-effectiveness of growth factors, NPWT and silver
dressings in the treatment of difficult-to-heal postsurgical
wounds in obstetrics and gynecology.
Materials and methods An extensive search of the Eng-
lish and Polish literature via PubMed and EMBASE
databases was undertaken for articles published between
January 1960 and April 30, 2014 to identify articles that
described and assessed use, efficacy and cost-effectiveness
of growth factors, silver dressings and NPWT in patients
with hard-to-heal postoperative wounds following obstetric
or gynecological surgery.
Conclusions Literature review regarding the use of
growth factors, NPWT and silver dressings suggests that
these methods may play an important role in the manage-
ment of wounds after invasive obstetric and gynecological
procedures. Obese patients, patients after vulvectomy or
prior radiation therapy may benefit most, however, due to
non-numerous randomized reports, prospective studies on
the use of above-mentioned methods in the treatment of
postsurgical wounds following obstetric and gynecological
interventions are required.
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Introduction
Postoperative wound healing complications constitute an
important medical and socioeconomic problem worldwide.
Despite the fact that the risk factors responsible for the
impaired healing process were identified and the con-
tinuously increasing medical knowledge in the fields of
tissue engineering, molecular biology and microbiology
facilitated the development of numerous new recommen-
dations and methods for management, in many cases the
available options for successful treatment of postoperative
wounds remain limited. Chronic, difficult-to-heal wounds
occurring as complications of various disorders associated
with insufficient oxygen and nutrient supply to the cells are
potential sources of infection and lead to necrosis of the
surrounding tissues. In consequence, non-treated or inap-
propriately treated postsurgical wounds may separate, lead
to formation of fistulas, or become sites of origin for sys-
temic infections. Patients are exposed to risk of further
complications and hospitalization time extends resulting in
increased treatment costs. Treatment prolongation affects
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also the quality of life and psychosocial functioning of
patients with impaired wound healing. Considering the
arguments above, appropriate management of postop-
erative wounds is currently one of the priorities for the
majority of invasive medical disciplines.
Obstetrics and gynecology are fields in which the issues
associated with wound healing are particularly relevant.
According to the literature data, the rate of infected, hard-
to-heal wounds for the two most common interventions in
obstetrics and gynecology, i.e., cesarean section and ab-
dominal hysterectomy, is 1.8–12.2 % with 0.3–1.2 % of
cases being associated with subsequent wound dehiscence
[1–12]. The less common procedure of vulvectomy with or
without accompanying inguino-femoral lymphadenectomy
is characterized by 12.5–39 % of cases of wound healing
disorders [13].
Recently formed concepts for the treatment of chronic
and difficult-to-heal wounds assume full comprehensive-
ness of therapy. This involves the need for systemic
treatment being undertaken simultaneously with direct
therapeutic activities at the site of the injury. The goal of
the systemic treatment is to ensure conditions that promote
healing by elimination of risk factors responsible for the
abnormal course of the wound healing process, including
infections, obesity, malnutrition, anemia and nicotinism, as
well as efficient treatment of concomitant diseases such as
diabetes, malignancy or autoimmune diseases.
According to the TIME strategy (tissue management,
infection and inflammation control, moisture imbalance,
epithelial advancement) developed by the European
Wound Management Association in 2004, topical wound
treatment involve the sequential stages of wound de-
bridement, infection control, maintaining appropriate
moisture and stimulation of epithelialization [14]. The
goal of wound debridement is to clear the wound bed of
foreign bodies, necrotic tissue and excessive exudate that
constitute potential sources of infections while also hin-
dering the development of granulation tissue and epithe-
lial edge advancement. Debridement may be either
invasive using surgical instruments, or conservative, in-
volving mechanical (hydrosurgery, low-frequency ultra-
sound), enzymatic (collagenase), autolytic (hydrogels,
honey), chemical [antiseptics, i.e., octenidine, chlorhex-
idine, silver, polyhexamethylene biguanide (PHMB)] or
larval methods [15]. Reduction of infection and the
indirectly associated inflammation control are achieved by
administration of prophylactic doses of antibiotics in the
perioperative period, postoperative use of antiseptic
dressings (silver, honey, iodine, or PHMB) and lavasepsis
consisting in cleansing the wound with antiseptics prior to
each dressing change [15, 16]. Maintaining appropriate
moisture balance, exudate management and promotion of
regeneration processes, such as epithelialization, are tasks
where crucial role is played by biologically active
dressings, and recently also by negative pressure tech-
niques [15].
The concept of active dressings was initiated and de-
veloped in 1962 by Winter, who demonstrated that moist
dressing environment accelerated re-epithelialization and
wound healing by a factor of two as compared with tra-
ditional dry dressings [17]. Studies conducted by Winter’s
successors confirmed his idea and led to the development
of an ‘‘ideal dressing’’ model. According to the model,
topical compress should not only provide for external
protection of the wound, but mainly stimulate the regen-
eration processes, e.g., by ensuring active wound debride-
ment, maintaining appropriate moisture with the
appropriate pH, gas exchange and thermal regulation
within the wound bed [18]. The ‘‘ideal dressing’’ should
also absorb excess exudate while causing no allergic re-
actions and being easy to place and remove so as not to
damage the wound edges upon replacement. As a result,
departure from the traditional methods of covering wounds
with dry gauze dressings that have no other role than
protective can be observed.
The proposed dressing model became a basis for the
research of new, efficient methods of wound management.
The most innovative methods include growth factors, pla-
telet-rich plasma (PRP) and derivatives, negative pressure
wound therapy (NPWT), and antiseptic silver dressings.
Numerous reports are available to evidence the efficacy of
these methods in the management of postoperative wounds,
e.g., in general, plastic and trauma surgery [19–22]. As far
as obstetrics and gynecology are concerned, the number of
published studies on the usefulness of the growth factors,
NPWT and silver dressings in the treatment of hard-to-heal
and infected wounds is still very low and insufficient.
Considering the number of procedures performed within
the pelvis minor region in females as well as the con-
tinuously increasing number of patients undergoing ce-
sarean section, analysis of the usefulness, efficacy and cost-
effectiveness of these methods for the treatment of post-




A review of the English and Polish literature was under-
taken for articles published between January 1960 and
April 30, 2014 to identify articles that described and
assessed use, efficacy and cost-effectiveness of growth
factors, silver dressings and negative pressure wound
therapy in patients with hard-to-heal (infected, dehisced)
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postoperative wounds following obstetric or gynecological
surgery.
Studies were identified via PubMed and EMBASE
databases using keywords: ‘‘growth factor,’’ ‘‘platelet rich
plasma,’’ ‘‘platelet gel,’’ ‘‘silver dressing,’’ ‘‘negative
pressure wound therapy’’ or ‘‘vacuum assisted closure’’
combined with ‘‘wound’’ and ‘‘obstetrics,’’ ‘‘gynecology,’’
‘‘hysterectomy,’’ ‘‘vulvectomy’’ or ‘‘cesarean section’’ by
two authors (PS, AW) independently. The reference lists of
retrieved articles were reviewed to locate additional
studies.
Study selection
A total of 507 potentially useful publications were identi-
fied including 92 duplicates (n = 415). Only studies de-
scribing growth factor, platelet-rich plasma, platelet gel,
silver dressing, negative pressure wound therapy or
vacuum-assisted closure use after hysterectomy, vulvecto-
my or cesarean section were considered relevant (n = 45).
Publications eligible for the study included full text: ran-
domized controlled trials, cohort studies, case report and
case series studies. Abstracts, conference supplements and
review articles were excluded. A total of 25 studies were
finally retained and reviewed in detail (Fig. 1).
Study analysis
Following data were collected: study design, patient
population, surgical intervention, method of treatment,
regimen, outcomes, follow-up, complications and statisti-
cal analysis. The characteristics of selected publications are
summarized in Table 1.
Growth factors in the management of hard-to-heal
postoperative obstetrical and gynecological
wounds
The modern concept of an ‘‘ideal dressing’’ assumes that
the dressing should not only play a protective role or
provide appropriately moist conditions, but also directly
stimulate cellular regeneration. Starting from the mid-
1980s, many researchers focused on cellular growth factors
and opportunities of their use in the treatment of chronic
wounds [23]. The growth factors being simultaneously
cytokines and biologically active peptides of auto- and
paracrine activity are characterized by pleiotropic effect on
the course of the healing process. By binding membrane
receptors of the target tissues, the growth factors trigger
intracellular signaling pathways and stimulate cellular
proliferation, differentiation and migration [19, 24, 25].
Importantly, the fact that growth factors do not penetrate
the cell interior and thus do not directly interact with the
nucleus eliminates the potential risk of mutagenic effects
and neoplasia.
Due to their wide spectrum of activities and the multi-
tude of functions, attempts are made to use growth factors
in the treatment of various disorders and diseases. This
mostly pertains to such disciplines as general surgery,
maxillofacial surgery, plastic surgery, orthopedics and
sports medicine as a consequence of the invasive nature
and related necessity to repair damaged tissue structures
[19, 20, 23, 26].
In 1997, the US Food and Drug Administration (FDA)
approved the recombinant human platelet-derived growth
factor BB (rhPDGF-BB, becaplermin) in adjunctive treat-
ment of diabetic neuropathic foot ulcers [20, 23]. To date,
this is the only cellular growth factor product to be ap-
proved for use in chronic wounds and ulcers management
on the basis of multicenter, randomized controlled trials.
Animal studies revealed that rhPDGF-BB significantly
accelerated the healing of wounds, including ischemic, and
that one of the possible mechanisms of its action involves
reduction of the levels of proinflammatory cytokines: tu-
mor necrosis factor-alpha (TNF-a), interleukin 1-beta (IL-
1b) and metalloproteinase 2 (MMP2) and 9 (MMP9) within
the wound [27]. Of the remaining growth factors, ker-
atinocyte growth factor (KGF), granulocyte macrophage
colony-stimulating factor (GM-CSF) and epidermal growth
factor (EGF) were clinically confirmed to be efficient in the
treatment of chronic venous ulcers [23]. The beneficial
effect of growth factors such as vascular endothelial
growth factor (VEGF) and transforming growth factor-beta
(TGF-b) on the wound healing process was demonstrated
only in animal studies [23]. This small number of con-
trolled, randomized trials conducted in appropriately large
group of patients does not permit any definite conclusions
regarding the efficacy of growth factors in the treatment of
abnormally healing wounds, including postoperative. On
the other hand, due to the high costs associated with
preparation of recombinant growth factors and with ap-
plication techniques preventing growth factors from being
degraded too early within the administration site, the
method will probably not be considered as the first-line
treatment of wounds after invasive procedures.
The platelet-rich plasma (PRP) which constitutes an
autologous concentrate of thrombocytes in a small volume
of plasma comprises an efficient alternative to growth
factors. Depending on the technique used PRP is charac-
terized by a two- to sixfold increase in the platelet count
[26, 28]. As a result, concentrations of growth factors
produced by thrombocytes are increased several times.
Most important growth factors found in the PRP include: 3
isomers of PDGF (PDGFaa, PDGFbb, PDGFab), TGFb1,
TGFb2, VEGF and EGF [26, 28]. Due to the low plasma
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volume, PRP contains also adhesion proteins such as fibrin,
fibronectin and vitronectin involved in the extracellular
matrix formation and thus being of importance for the
wound healing process. Results of in vitro and animal
studies revealed the effect of platelet-rich plasma on the
migration, proliferation and differentiation of cells in-
volved in the healing process as well as angiogenesis-s-
timulating properties [28]. The efficacy of PRP was shown
to depend mostly on appropriate preparation technique that
ensures a possibly highest level of platelets per unit volume
without their simultaneous degradation. To date several
systems for PRP preparation were developed with only few
of them allowing to achieve the required ‘‘therapeutic’’
platelet concentration of C1 9 106/ll [26]. The process for
preparation of platelet-rich plasma generates much less
costs compared to genetic engineering methods used in
Fig. 1 Diagram detailing
literature search and study
inclusion/exclusion criteria. GF
growth factor, PRP platelet-rich
plasma, PG platelet gel, SD
silver dressing, NPWT negative
pressure wound therapy, VAC
vacuum-assisted closure
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Table 1 Characteristics of studies included in the review
No. References Study design Patient population/surgical
intervention
Method of treatment Regimen
1. Shackelford
et al. [36]
RCT 24 patients with wound
separation after CS or
benign abdominal
gynecologic procedures;
n = 12 treatment group,
n = 12 control group
0.01 % rhPDGF-BB gel or placebo Topical daily application





110 patients after major
gynecologic, surgery;
n = 55 study group, n = 55
historical control group
Surgery ? APTG or surgery alone Direct postoperative
application to the surgical
site
3. Morelli et al.
[43]
Retrospective 25 patients after RVIFL;
n = 10 study group, n = 15
control group
Surgery ? PG or surgery alone Direct postoperative







22 patients after RVIFL;
n = 11 study group, n = 11
historical control group
Surgery ? rhG-CSF or surgery alone 300 lg/day subcutaneously
1 day before surgery, on the
day of surgery and daily for




RCT 40 patients after RVIFL;
n = 20 study group, n = 20
control group
Surgery ? rhG-CSF or
surgery ? placebo
300 lg/day subcutaneously
1 day before surgery, on the
day of surgery and daily for
7 consecutive days after
surgery
6. Argenta et al.
[53]




P2: wound dehiscence after
TAH ? BSO for
endometrial cancer






VAC P1, P2, P3: intermittent
negative pressure of
125 mmHg; dressing
replacement every 48 h
7. Miller et al.
[54]




NPWT Negative pressure of
80 mmHg for 6–8 h daily; 3
dressing replacements per
week
8. Stannard et al.
[55]
Case series 2 patients
P1: BMI 50 kg/m2 after
TAH ? BSO for
endometrial cancer
P2: BMI 60 kg/m2 after
TAH ? BSO for
endometrial cancer
Prophylactic NPWT Continuous negative pressure




Case report 67 years old patient, BMI
41 kg/m2, fascial
dehiscence and skin defect






VAC Dressing replacement every
48 h
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Table 1 continued
No. References Study design Patient population/surgical
intervention
Method of treatment Regimen
10. Lavoie et al.
[57]
Case report 73 year old patient, BMI
50 kg/m2, with wound
hematoma and adipose
tissue necrosis after
TAH ? BSO for
endometrial cancer
NPWT with gauze filler NA
11. Schimp et al.
[58]
Retrospective 27 patients with complex
wound failures after
TAH ? BSO (n = 14), RV
with or without IFL
(n = 5), skin or
myocutaneous grafting
(n = 3), parastomal
herniorrhaphy (n = 2),
retroperitoneal lymph node
dissection (n = 2), drainage
of gluteal abscess (n = 1)
VAC Negative pressure of
50–125 mmHg applied
directly after reoperation
(n = 4) or after wound
failure (n = 23); dressing
replacement every 48 h
12. Narducci
et al. [59]
Retrospective 54 patients after RV or wide
local vulvectomy with or
without IFL and/or
myocutaneous grafting;
study group (n = 30),
control group (n = 24)
VAC or conventional care (perineal
irrigation and air drying)
Continuous negative pressure
of 100–125 mmHg applied
within 24 h of surgery;
dressing replacement every
48–72 h
13. Riebe et al.
[60]
Case series 2 patients
P1: after palliative tumor
debulking with IFL for
locally advanced vulvar
cancer
P2: after RVIFL for locally
advanced vulvar cancer
Polypropylene mesh
implantation ? prophylactic VAC
Continuous negative pressure






Case report 41 year old patient after
vulvectomy for recurrent
Paget’s disease
VAC ? split-thickness skin graft Negative pressure of
50–125 mmHg applied
directly after surgery and
skin grafting; dressing
replacement every 48 h
15. Dainty et al.
[62]
Case series 7 patients including 4 patients
after vulvectomy for
Paget’s disease (n = 2) or
hidradenitis suppurativa
(n = 2)
Fibrin tissue adhesives ? VAC ? split-
thickness skin graft
Intermittent negative pressure
of 100 mmHg applied
directly after surgery and
skin grafting for 3–4 days
16. Piovano et al.
[63]









50 patients after CS with BMI
[35 kg/m2
Prophylactic NPWT Direct postoperative
application to the surgical
site for 7 days
18. Mark et al
[65]
Retrospective 63 patients after CS with BMI
[45 kg/m2; n = 21 study
group, n = 42 control
group
Prophylactic NPWT or standard surgical
dressing
Direct postoperative
application to the surgical
site
19. Nissman et al.
[66]
Case report 27 year old patient after CS;
BMI = 32 kg/m2;
necrotizing fasciitis
Surgery ? NPWT NA
20. Durai et al.
[67]
Case report 31 year old patient after CS;
necrotizing fasciitis
Surgery ? VAC Negative pressure therapy for
a minimum of 2 weeks
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Table 1 continued
No. References Study design Patient population/surgical
intervention
Method of treatment Regimen
21. Ottosen et al.
[68]
Prospective 10 patients including 4
patients with wound
infection/rupture after CS
NPWT Negative pressure therapy for
a minimum of 2 days in an
outpatient setting
22. Lewis et al.
[69]
Retrospective Historical cohort of 431
patients after laparotomy
for endometrial cancer; 134
patients with wound
complications (31 %)
Prophylactic NPWT or routine care Direct postoperative
application to the surgical
site; negative pressure
therapy for 4–7 days
23. Beral et al.
[70]
Case report 67 year old patient with
superficial wound
dehiscence after
TAH ? BSO for ovarian
cancer
VAC Negative pressure therapy for
15 days; dressing
replacement every 72 h;





Case series 3 patients
P1, P2: wound infection after
RV
P3: wound infection after
abdominal hysterectomy
Autolytic
debridement ? lavasepsis ? metallic-
coated SD
P1, P2, P3: dressing
replacement every 48–72 h
25. Connery et al.
[80]
Retrospective 72 patients after CS; n = 36
study group, n = 36 control
group
Metallic-coated SD or gauze pad Direct postoperative
application to the surgical
site
No. References Outcomes Follow-up Complications Statistical analysis
1. Shackelford
et al. [36]
29 ± 14 days of therapy in
treatment group vs.
47 ± 24 days in control group
(p = 0.057); complete wound
closure after 35 ± 15 days of
therapy in treatment group vs.
54 ± 26 days in control group
(p = 0.05); more rapid wound
closure in treatment group
3 patients lost to follow-up
(1 in treatment group, 2 in
control group)





2. Fanning et al.
[37]
Significant reduction in pain on
postoperative day 0 and 1
(p B 0.001); significant
reduction in total dose of
morphine (p = 0.02)






exact test, Student t test
3. Morelli et al.
[43]
Significant decrease in wound
infection, necrosis and
breakdown rates (p = 0.032;
p = 0.096; p = 0.048,
respectively); significant
decrease in postoperative fever
rate and hospital stay
(p\ 0.001); complete wound
closure after 24 days of
therapy in study group vs.
93 days in control group
(p\ 0.001)
NA NA Chi-square test, Fisher
exact test, Student t test
4. van Lindert
et al. [44]
Primary wound healing observed
in 69.7 % of vulva and groin
wounds in study group vs.
25 % in control group; major
wound breakdown observed in
6.1 % of vulva and groin
wounds in study group vs.
50 % in control group





observed in 6.1 % and
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Table 1 continued




observed with respect to
wound infection and primary
wound healing rates; no
significant differences
observed with respect to
quality of life; total treatment
cost in study group EUR
15,951 vs. control group EUR
12,430
Follow-up on day 30 and 56
postoperatively; 1 patient
in study group excluded; 3





Student t test, Mann–
Whitney test
6. Argenta et al.
[53]
P1: significant decrease in
wound volume after 14 days of
therapy; complete wound
closure 4 weeks postdischarge
P2: significant decrease in
wound volume after 10 days of
therapy; complete wound
closure
P3: significant decrease in
wound volume after 13 days of
therapy, fistula closure on day
7 of therapy; complete wound
closure
In all patients enhanced
granulation tissue formation
was observed within the first
48 h of VAC therapy




7. Miller et al.
[54]
Wound closure after 3 months;
no analgesics required
3 months NA NA
8. Stannard et al.
[55]




P1: 4 weeks postoperatively







Complete fascial closure after
21 days
3 months None NA
10. Lavoie et al.
[57]
7 days of therapy; patient
discharge after 36 days
following debridement;
complete wound closure after
82 days following
debridement; no skin grafting
required
2 months None NA
11. Schimp et al.
[58]
96 % reduction in the median
size of wound defect; median
VAC therapy length 32 days
(range 3–88 days); at the time
of last contact 26 of 27 patients
presented complete wound
healing
Median follow-up 52 days
(range 0–270 days)
Bleeding (1 patient); 67 %
of patients complained





Median VAC therapy length
11 days (range 6–38 days);
complete wound closure after
44 ± 18 days of therapy in
study group vs. 60 ± 29 days
in control group (p = 0.0175);
no significant difference in
length of hospital stay
Median follow-up
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preparation of recombinant growth factors while the au-
tologous nature of the product eliminates the risk of
transmission of viral infections, such as hepatitis virus or
HIV infection.
Discussed below are the attempts made hitherto with
regard to the use of cellular growth factors and PRP
derivatives in the treatment of difficult-to-heal postsurgical
obstetrical and gynecological wounds.
Table 1 continued
No. References Outcomes Follow-up Complications Statistical analysis
13. Riebe et al.
[60]
P1: granulation tissue reached
skin level on 32 postsurgical
day
P2: granulation tissue reached
skin level on 39 postsurgical
day
10 months None NA
14. Shvartsman
et al. [61]
16 days of therapy; successful
graft adherence
12 months None NA
15. Dainty et al.
[62]
*90 % graft-take rate (3
patients)
*60 % graft-take rate (1
patient)






16. Piovano et al.
[63]
4 weeks of therapy; complete
wound healing
12 months None NA
17. Bullough
et al. [64]
No SSI observed; no hospital
readmissions
*1 month Allergic reaction (2
patients)
NA
18. Mark et al
[65]
Decrease in wound complication
rate 0 % study group vs.
10.4 % control group
(p = 0.15)
1 month None Chi-square test, Student
t test
19. Nissman et al.
[66]
Complete wound healing NA None NA
20. Durai et al.
[67]
Complete wound healing 6 weeks None NA
21. Ottosen et al.
[68]
Treatment experienced as
effective; high level of
dependency on the equipment
at the beginning of therapy;
experience of embarrassment;
importance of relatives help
and support




22. Lewis et al.
[69]
Mean overall cost of incision
care following NPWT $509 vs.
routine care $613
NA Risk of skin blistering
following NPWT
estimated at 20 %
Assumption of 50 %
reduction in risk of
wound complication
following NPWT
23. Beral et al.
[70]
Wound healing with purulent
discharge






P1, P2: complete wound healing
P3: complete wound healing
after 14 days
Treatment outcomes






25. Connery et al.
[80]
No significant difference
observed with respect to SSI
rate between both groups
1 month; no one lost to
follow-up
SSI (2 patients in study




RCT randomized controlled trial, CS cesarean section, rhPDGF-BB recombinant human platelet-derived growth factor BB, NA not applicable,
APTG autologous platelet tissue graft, RVIFL radical vulvectomy with inguino-femoral lymphadenectomy, PG platelet gel, rhG-CSF recom-
binant human granulocyte colony-stimulating factor, TAH total abdominal hysterectomy, TAH ? BSO total abdominal hysterectomy with
bilateral salpingo-oophorectomy, VAC vacuum-assisted closure, NPWT negative pressure wound therapy, BMI body mass index, SSI surgical site
infection, SD silver dressing
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Laparotomy
Laparotomy, or surgical opening of the abdominal cavity,
is one of the most commonly performed surgical proce-
dures. Among patients admitted to gynecological wards,
main reasons for exploration of the abdominal cavity in-
clude benign and malignant tumors within the uterus and/or
adnexa, abnormal vaginal bleedings and endometriosis [6,
29]. A preferred method for the management of most of the
aforementioned disorders is abdominal hysterectomy being
at the same time the most common invasive procedure in
gynecological surgery. According to literature data, nearly
one in five women is subjected to hysterectomy before the
age of 60 [30].
In obstetrics, the abdominal cavity is opened during
cesarean section procedure. Depending on the geographical
region, the ratio of cesarean sections to the total number of
deliveries varies between 15 and 30 %, with a significant
upward trend being observed in the developed countries
[31, 32].
Both the gynecological surgeries involving laparotomy
and the cesarean section are procedures relatively often
complicated by impaired postoperative wound healing. In
case of abdominal hysterectomy, the percentage of post-
operative wound infections is 3.0–12.2 %, with wound
dehiscence occurring in 0.3–0.6 % patients [1–7, 29]. Ce-
sarean section is associated with risk of the above-men-
tioned complications of 1.8–11.3 % and 0.4–1.2 %,
respectively [1, 8–12, 33].
Risk factors responsible for abnormal healing of ob-
stetric and gynecological postoperative wounds are similar
to those observed in other surgical disciplines. They in-
clude i.a. elderly age, obesity, diabetes, malnutrition, in-
fections (chorioamnionitis in case of cesarean section),
immunodeficiency, anemia, renal and hepatic insufficiency,
nicotinism, prior radiation therapy and intraoperative
technical difficulties extending the overall time of proce-
dure [1, 5, 18, 34, 35]. The size and location of the wound,
type of materials used for wound closure and presence of
drains are also of high importance.
Although being sparse, studies conducted with regard to
the use of growth factors after obstetric and gynecological
procedures demonstrate their beneficial effect on wound
healing [36, 37]. A double-blinded randomized, placebo-
controlled trial performed by Shackelford et al. evaluating
rhPDGF-BB efficacy in the treatment of separated surgical
wounds after cesarean section or benign abdominal gyne-
cologic procedures revealed a significant reduction in time
required for complete wound healing in women receiving
the recombinant growth factor [36]. Among 11 patients in
the study group, daily topical application of 0.01 %
rhPDGF-BB gel resulted in the mean time until wound
closure of 35 ± 15 days compared to 54 ± 26 days in the
placebo group (p = 0.05). Taking into account the differ-
ence between the time of procedure and the time of wound
dehiscence occurrence, the overall treatment time was
29 ± 14 days in the study group and 47 ± 24 days in the
control group (p = 0.057).
Fanning et al. conducted a prospective non-randomized
study evaluating the toxicity of autologous platelet tissue
graft—a derivative of platelet-rich plasma, and its efficacy
in decreasing postoperative pain in patients after major
gynecological surgeries, e.g., laparoscopic-assisted vaginal
hysterectomy, laparoscopic-assisted vaginal hysterectomy
with laparoscopic lymphadenectomy, abdominal hysterec-
tomy as well as advanced urogynecological procedures
requiring multiple repairs [37]. At completion of the sur-
gical procedure and achievement of adequate hemostasis,
the researchers applied a pre-prepared and activated au-
tologous platelet tissue graft directly to the surgical site,
including the vaginal cuff, parametrium and fascia. No
adverse effects of the treatment were observed in the group
of 55 patients who received the autologous platelet tissue
graft. Pain experienced on the day of surgery and during
the first postoperative day assessed using a ten-point visual
analog scoring system was significantly reduced in the
study group compared to the control group: 2.7 and 2.1 vs.
6.7 and 5.5 (p\ 0.001), respectively. An indirect conse-
quence of these outcomes was the reduction in total dose of
morphine used to relieve postoperative pain during hospi-
talization from 26 mg in the control group to 17 mg in the
study group (p = 0.02).
Vulvectomy
Vulvar cancer is a relatively rare malignancy of female
genital organs, accounting for ca. 5 % of all cases [38].
According to data collected in the Polish Register of
Cancer, 463 new cases (standardized morbidity ratio of
1.06/100,000) and 270 deaths (standardized mortality ratio
of 0.54/100,000) due to vulvar cancer were recorded in
2011 [39]. As a result, vulvar cancer is the 23rd most
common malignancy in Polish women while being the 21st
most common cause of deaths.
Following publication of results obtained by Way in
1960, radical vulvectomy with bilateral inguino-femoral
lymphadenectomy is considered standard treatment for
most patients with advanced cancer of the vulva [38, 40].
Due to surgical site location, extent and mutilatory char-
acter, procedure is associated with numerous postoperative
complications [13]. Abnormal healing of groin wounds
leading to wound breakdown is the most common com-
plication of radical vulvectomy at the early stage. Ac-
cording to first clinical observations, wound complications
(infection, dehiscence) occurred in 53–85 % of patients
undergoing radical surgery of the vulva [41, 42]. Later
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implementation of three separate incision technique al-
lowed for a marked reduction in this percentage and cur-
rently, infections or dehiscence of postoperative wounds
are observed in 21.3–39 % and 12.5–39 % of patients
subjected to vulvectomy, respectively [13]. Inguino-
femoral lymphadenectomy is considered to be the main
reason behind the large percentage of wound healing dis-
turbances. Due to the moist and warm groin environment,
the dissection of inguinal lymph nodes increases the risk of
wound infection while also leading to chronic lymphedema
development. The remaining factors that impede the heal-
ing process in patients undergoing radical vulvectomy in-
clude central or bilateral tumor location, en bloc surgery,
extent of lymphadenectomy, presence of lymphocele, re-
section of the saphenous vein and prior radiation therapy
[13].
There are few reports on the use of cellular growth
factor products in the treatment of wounds resulting from
radical vulvectomy. Retrospective study conducted by
Morelli et al. in a group of 25 patients with vulvar cancer at
clinical stage IB and II subjected to radical vulvectomy
with inguino-femoral lymphadenectomy revealed that ap-
plication of a platelet gel before the reconstructive phase of
surgery accelerates wound healing [43]. In 10 patients in
whom platelet gel was used before the reconstructive phase
of surgery, a significant decrease in wound infections,
necrosis and dehiscence rates was observed as compared to
the control group (30 vs. 73.3 %, p = 0.032; 20 vs.
53.3 %, p = 0.096; 20 vs. 60 %, p = 0.048, respectively).
Significantly shortened hospital stays and shorter times
until complete wound healing were also noted (6.4 vs.
17.6 days, p\ 0.001 and 23.6 vs. 93.3 days, p\ 0.001,
respectively). In the opinion of the authors, the platelet gel
as a reproducible, low-cost and minimally invasive tech-
nique comprises an efficient alternative to myocutaneous
flaps.
Results similar to those reported by Italian researchers
were observed by van Lindert et al. who used the recom-
binant human granulocyte colony-stimulating factor (r-
metHuG-CSF, filgrastim) in women subjected to radical
vulvectomy with bilateral inguino-femoral lymphadenec-
tomy [44]. In a pilot study in a group of 11 patients who
received filgrastim in the perioperative period (7 days in
total) at the daily dose of 300 lg subcutaneously, the au-
thors observed a reduction in the rates of postoperative
dehiscence of inguinal and vulvar wounds as compared to a
historical control group. Out of the total number of 33
wounds in the study group, 69.7 % showed primary wound
healing and significant dehiscence was observed in 6.1 %
of cases. In the group of patients treated with the standard
regimen, the respective values were 25 and 50 %.
The pilot study became a starting point for a multicenter,
randomized trial conducted in 2004 to assess the efficacy of
filgrastim for wound infections prevention and the effect of
the treatment on the quality of life of the patients and the
overall treatment costs after radical vulvectomy with in-
guino-femoral lymph nodes dissection [45]. Similar as in
the previous study, filgrastim was administered subcuta-
neously in the perioperative period at the dose of
300 lg/day for a total of 9 days. The analysis did not
confirm a positive effect of G-CSF on the reduction of
infected wounds rates. In the group of 16 patients receiving
filgrastim, infections of wounds were observed in 57.1 %
of cases while primary wound healing was observed in
14.3 %. In the control group of 20 subjects receiving
placebo, the respective values were 55.6 and 33.3 %. In
addition, no differences were demonstrated with regard to
the quality of life of patients in both groups, while the
overall treatment costs were higher in the G-CSF group
(EUR 15,951 vs. 12,430).
In conclusion, results of studies on the use of growth
factors in the treatment of wounds after laparotomy and
vulvectomy as discussed above provide no unambiguous
answer with regard to the efficacy and usefulness of these
agents. Data collected to date suggest a possible beneficial
effect of rhPDGF and platelet-rich plasma derivatives in
the prevention and treatment of wound complications in
patients after procedures characterized by high risk of ab-
normal wound healing, e.g., due to vulvar cancer; however,
costs of such treatment should be analyzed. Randomized
controlled trials conducted in appropriately large patient
groups are lacking with regard to the use of cellular growth
factors in the treatment of difficult-to-heal wounds fol-
lowing obstetric and gynecological surgeries and stan-
dardization of procedures for preparation and application
of growth factors is required.
Negative pressure wound therapy—an alternative
to the standard regimens of postsurgical
obstetrical and gynecological wound management
First reports on the possible use of negative pressure as a
method to treat chronic and difficult-to-heal wounds date
from the late 1980s. Study conducted by Kostiuchenko
et al. demonstrated beneficial effect of vacuum used as
supportive therapy to surgical debridement in the man-
agement of infected wounds [46]. In a group of 116 pa-
tients subjected to experimental treatment, placing a
suction pump at the wound surface generating a negative
pressure of 100 mmHg for 5–10 min both before and after
the debridement procedure, better healing results were
observed as compared to the group of 105 patients treated
in the standard manner.
The concept of the Russian researchers was confirmed
by an animal model study published in 1997 by Morykwas
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et al. [47]. Application of subatmospheric pressure of
125 mmHg contributed to a fourfold increase in blood flow
within the wound bed as well as to significant reduction in
the tissue bacterial counts within the wound area from 108/
g of tissue to 105/g of tissue after 4 days of treatment.
Similar result in the control group was noted after 11 days
of treatment (p\ 0.05). In addition, a statistically sig-
nificant acceleration of granulation tissue formation was
observed in comparison with the control group—an in-
crease of 63.3 % upon continuous negative pressure and of
103 % upon intermittent negative pressure application
(p\ 0.05).
A study conducted in the same year with the use of the
same methodology to assess the clinical efficacy of NPWT
in a group of 300 wounds (175 chronic wounds, 94 sub-
acute wounds, and 31 acute wounds) revealed favorable
response to the treatment in 296 cases. A reduction in the
edema was observed in the wound region while also con-
firming the previously observed increase in blood flow and
enhanced formation of granulation tissue [48].
Today, NPWT is a worldwide-established method for
the treatment of chronic and difficult-to-heal wounds with
efficacy confirmed by numerous clinical studies [21, 22,
49, 50]. Similar to growth factors, negative pressure affects
processes determining proper wound healing by providing
moist environment, increasing blood perfusion, accelerat-
ing the formation of granulation tissue and removing ex-
cess exudate from the site of the injury, thus indirectly
reducing the risk of infection [47, 48, 51]. As a result, the
list of NPWT indications is being continuously extended.
In 1995, FDA approved NPWT as a method to treat acute
and chronic post-traumatic wounds and burns were added
to the list of indications 7 years later [49].
Over the years, numerous negative pressure systems
have been developed. A standard kit includes a porous
polyurethane foam, an adhesive sealing film, a drain, a
vacuum pump and a container for secretions. Depending on
the intended use, the devices may be either stationary or
mobile, and the negative pressure may be dosed in either
constant or intermittent manner, usually within the range of
50 mmHg down to 150 mmHg [49, 50, 52]. The most re-
cent models of vacuum-assisted closure devices facilitate:
ambulatory use, removal of larger quantities of the secre-
tion and irrigation of the wound site with antibiotic solution
and/or local anesthetics; antiseptic silver-coated sponges
are also used [49, 50, 52].
Contraindications to NPWT include malignant lesions
and extensive necrosis in the wound region, osteomyelitis,
fistulas and exposed blood vessels, nerves, bones, or organs
[50, 52]. Therefore, it is important to remove necrotized
tissue from the wound bed and cover the exposed structures
with a non-adherent material, e.g., a silicone dressing prior
to applying negative pressure. This barrier material would
additionally protect the tissues from growing into the
polyurethane foam [50, 52]. In cases of wound infections, it
is important to provide local and/or systemic treatment
with antiseptic dressings, antifungals or antibiotics and
similar to other methods used in wound management,
treatment of concomitant diseases combined with
elimination of factors disturbing normal healing, e.g., by
controlling metabolic disorders due to diabetes or malnu-
trition is an inseparable part of vacuum therapy [50].
Adverse events are rarely observed with NPWT. Those
most common include tissue necrosis, fistula formation as
well as pain and bleeding accompanying dressing change
due to granulation tissue ingrowth into the foam [50, 52].
The latter two may be prevented by the use of interface
dressings separating the tissues from the material filling in
the wound bed. Other procedures used in pain management
involve reduction in suction power by ca. 25 mmHg,
saturation of the dressing with 0.9 % sodium chloride or
1 % lidocaine solution 15–30 min before the planned
dressing change, covering the wound bed with hydrogels as
well as more frequent dressing changes and premedication
with analgesic agents [50, 52].
Similar as in the case of growth factors, the number of
studies on the use of NPWT in the treatment of difficult-to-
heal obstetric and gynecological postsurgical wounds is
low. One of the first reports includes a case series de-
scription of complex wound failures after major gyneco-
logic procedures by Argenta et al. [53]. Application of
vacuum-assisted closure (VAC) device in three patients
who had experienced abnormal wound healing during the
postoperative period demonstrated good tolerance and high
efficacy with regard to granulation tissue formation within
the first 48 h since the initiation. No adverse effects of
therapy were observed, and satisfactory results of treatment
were obtained despite numerous burdens of patients in-
cluding morbid obesity, diabetes or ongoing chemotherapy.
It is noteworthy that in one case the use of subatmospheric
pressure resulted in closure of an enterocutaneous fistula
considered to be a contraindication to VAC therapy.
Miller et al. reported a clinical case of wound dehis-
cence in a moderately obese patient subjected to abdominal
hysterectomy in whom negative pressure of 80 mmHg
applied for 6–8 h daily contributed to complete healing of
the wound after 3 months of treatment [54]. During the
entire treatment period involving three dressing changes
per week, the patient required no analgesics which, ac-
cording to authors, supports the idea of using lower
vacuum levels than generally accepted. In a case series
study by Stannard et al., the authors suggested a possibility
of a prophylactic use of NPWT directly after the surgery
(continuous negative pressure of 125 mmHg for 4 days) to
prevent wound infection and breakdown in morbidly obese
patients subjected to abdominal hysterectomy [55]. In
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another case report by Gourgiotis et al. the application of
topical VAC therapy in patient with abdominal compart-
ment syndrome and skin defect following major gyneco-
logic surgery reduced the need for fluids and vasopressor
agents, prevented fascial retraction and visceral adherence,
and finally enabled delayed fascial closure [56]. Lavoie
et al. presented effective use of NPWT with gauze filling in
the case of extensive adipose tissue necrosis following
abdominal hysterectomy [57].
In 2004, Schimp et al. published a report on the efficacy
of VAC device in patients subjected to major gyneco-
logical procedures, such as total abdominal hysterectomy
with bilateral salpingo-oophorectomy and vulvectomy with
or without an inguinal lymph node dissection in whom
complex wound failures occurred during the postoperative
period [58]. A retrospective study included a group of 27
women; 25 diagnosed with malignant tumors of the uterine
cervix, endometrium, ovary and vulva. In 23 cases, VAC
device was used upon wound dehiscence occurrence (range
0–88 days postoperatively); in the remaining 4 patients
vacuum device was placed directly after the reoperation; in
3 women, the dehiscence was located in a previously ir-
radiated area, and wound infection was clinically con-
firmed in 10 patients. The range of negative pressure used
was between 50 and 125 mmHg; dressings were changed
in 2-day intervals, occasionally after premedication with
oral analgesics. The mean period of vacuum use in the
study was 32 (3–88) days; during this time, the authors
observed a significant reduction in the size of the wound—
96 % reduction as compared to the baseline area. In one
case, the treatment was discontinued due to bleeding, while
67 % of the remaining patients complained of pain that
accompanied dressing changes. No other complications or
treatment-emergent adverse effects were observed. At the
time of last visit (mean follow-up: 52 days), 96 % of pa-
tients presented complete wound healing.
In a retrospective non-randomized study conducted by
Narducci et al. in a group of 54 women subjected to radical
vulvectomy or wide local vulvectomy with defect volume
larger than 40 cm3, inguinal lymphadenectomy and/or
myocutaneous flap reconstruction, the authors observed a
statistically shorter time until complete wound healing after
VAC therapy as compared with the standard management
consisting in irrigation of the surgical site with 0.9 %
sodium chloride and air drying [59]. Among 30 patients (2
with previous radiotherapy history) in whom constant
subatmospheric pressure of 100–125 mmHg was started
within the first 24 h after the surgery, the overall time until
complete wound healing was 44.4 ± 18.4 days compared
to 60.2 ± 28.7 days in a control group of 24 subjects
(p = 0.0175). The mean duration of therapy involving
dressing changes at intervals of 48–72 h performed under
local or neuroleptic anesthesia was 11 (range 6–38) days.
No statistically significant difference was observed with
respect to the mean hospital stay between both groups.
Complications of VAC observed by the authors included
several cases of vestibular stenosis and one case of partial
necrosis of the myocutaneous flap used for vulvar
reconstruction.
Riebe et al. presented case series study regarding two
patients with locally advanced vulvar cancer who received
extensive surgical treatment including tumor debulking and
inguino-femoral lymphadenectomy [60]. After polypropy-
lene mesh was implanted over the exposed blood vessels
followed by VAC system application, authors observed
faster wound healing with lack of complications. Taking
into account the fact that exposed vessels, similarly as
fistulas, used to be considered as contraindications to VAC
therapy initiation these observations provide new evidence
regarding possibility to use subatmospheric pressure in the
treatment of hard-to-heal gynecologic wounds.
Single reports present effectiveness of NPWT combined
with split-thickness skin grafting after surgical treatment of
rare diseases of the vulva such as Paget’s disease,
hidradenitis suppurativa or syringoid eccrine carcinoma
[61–63].
NPWT was shown to be effective in preventing surgical
site infections (SSIs) in women after cesarean section.
Administration of single-use NPWT for 7 days postop-
eratively in 50 patients prevented SSIs and consequently
readmissions to the hospital in the high-risk group of
women with BMI C35 kg/m2 [64]. In a retrospective co-
hort study conducted by Mark et al. including 63 patients
after cesarean section with BMI of[45 kg/m2, the use of
NPWT reduced the percentage of wound complications
from 10.4 % in the control group to 0 % in the study group
(p = 0.15) [65]. On the other hand, significantly longer
duration of surgery and lower percentage of scheduled
cesarean sections were observed in the control group,
possibly contributing to the higher rate of complications.
Single attempts were made to use subatmospheric
pressure in the treatment of necrotising fasciitis in women
after cesarean section [66, 67]. As a result of a complex
management strategy including surgical debridement of
necrotic tissue, use of broad-spectrum antibiotics with si-
multaneous negative pressure therapy wounds were com-
pletely healed in two patients who had been diagnosed with
this potentially life-threatening infection in the postop-
erative period [66, 67].
A team of Danish researchers presented interesting
study regarding psychosocial aspects of NPWT among
patients in an outpatient setting [68]. Based on an analysis
and interpretation of individually collected interviews of 10
patients with wound healing disorders including four pa-
tients after cesarean section i.a. the efficacy of therapy and
its impact on everyday functioning, need for relatives care
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and support, and ability to manage a device were assessed.
The study indicated that in general, patients considered
NPWT to be effective, and despite the fact that it was
associated with a feeling of dependence at the beginning,
therapy became more acceptable with time. Importantly, all
patients reported a feeling of embarrassment during social
situations due to a device being present. With regard to
patients after cesarean section who at the same time
comprised a group of young mothers, help and support of
their relatives were extremely important.
Finally, single reports analyzing the costs of vacuum
therapy in obstetrics and gynecology suggest economic
benefits of the treatment. A study conducted by Lewis et al.
using the theoretical model to assess the costs of care using
prophylactic NPWT in a group of 431 patients after la-
parotomy due to gynecological malignancy revealed the
cost-effectiveness of such management amounting to $104
savings per one patient compared to the routine manage-
ment with the assumption of 50 % treatment efficacy [69].
The generated savings were even higher in the group of
obese and morbidly obese patients; in authors’ opinion, this
group of patients may benefit most from prophylactic
NPWT.
Despite unquestionable benefits of NPWT it is necessary
to pay special attention to iatrogenic mistakes that might
occur during treatment as evidenced by Beral et al. who
reported a case of abnormal wound healing as a conse-
quence of retained foam pieces in patient after total ab-
dominal hysterectomy [70]. Taking into account
radiolucent nature of the foam making subsequent detec-
tion difficult as well as the fact that often many fragments
are used to fill in the wound bed it seems reasonable to
record the number of removed foam pieces during each
dressing replacement.
Summarizing all written above, the review of available
literature leads to a conclusion that negative pressure
wound therapy constitutes a promising alternative to the
standard wound management regimens in obstetrics and
gynecology. Vacuum therapy appears to be particularly
beneficial in the group of obese patients, patients under-
going radical vulvectomy, vulvar reconstruction and pa-
tients with history of radiation therapy. In women after
cesarean section and with risk factors responsible for ab-
normal wound healing, prophylactic NPWT may prevent
surgical site infections and additional hospital stay, reduce
treatment costs and, what is equally important, permit the
patient to fulfill her role as a mother without any restric-
tions. Similar as in the case of growth factors, there are not
enough randomized controlled trials to justify the use of
NPWT in everyday clinical practice while simultaneously
analyzing the effect of the vacuum therapy on the overall
treatment costs. It is necessary to develop a unified regimen
for the use of NPWT, defining the optimum negative
pressure levels, dressing type, dressing change intervals
and treatment duration depending on the type of the
wound. It also appears reasonable to explore the possi-
bilities of using NPWT in combination with other wound
treatment methods, such as growth factors or antiseptic
dressings.
Silver dressings—state-of-the-art antiseptic
dressings in obstetrical and gynecological practice
Infections are one of the main factors responsible for im-
paired postoperative wound healing. In the conditions of
intact integuments integrity, the epidermis acts as a me-
chanical barrier against pathogenic microorganisms sup-
ported by the acidic environment and physiological
bacterial flora on the skin surface. However, as the skin is
incised, these mechanisms of protection lose their rele-
vance and the wound becomes an open gate for pathogens.
Endo- and exotoxins produced by microorganisms alter the
course of healing, simultaneously depleting local environ-
ment of oxygen and nutrients. The inflow of inflammatory
cells into the wound, stimulated by the presence of
pathogens crucial in the initial phase of healing, may fur-
ther enhance hypoxia, inhibit the activity of growth factors
and extend the overall healing time if the infection pro-
longs. As a result, a negative feedback loop is activated,
with oxygen deficiency causing tissue necrosis within the
wound and promoting growth of pathogenic microorgan-
isms. In addition, depletion of oxygen impairs the host cell-
mediated response of leukocytes and makes the local mi-
croenvironment prone to colonization by anaerobic bacte-
ria [71].
The risk factors for the surgical site infection are similar
to the factors impairing normal wound healing process as
discussed in introduction and include: elderly age, obesity,
diabetes, malnutrition, anemia, nicotinism, renal and liver
impairment, immunosuppression, irradiation as well as the
size, depth and location of the wound, duration of the
surgery, type of suturing materials used, presence of drains,
damage and hypoperfusion of the surrounding tissues, free
spaces left and insufficient hemostasis [5, 71, 72]. Hair
shaving, particularly on the day before the procedure, is
responsible for the increased percentage of SSIs, as is
prolonged hospitalization [2, 5, 72]. Since the risk factors
of wound infection are similar to factors responsible for
disturbances in normal healing process, it appears reason-
able to treat every case of a chronic, difficult-healing
wound as potentially infected.
According to the guidelines of the Centers for Disease
Control and Prevention, postoperative wounds in obstetrics
and gynecology are classified as clean-contaminated [72].
Literature data estimate the incidence of infected wounds
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in obstetrics and gynecology at 1–4 % to 8–12 % [1, 7, 10–
12]. With regard to the two most common procedures—
abdominal hysterectomy and cesarean section, SSIs rates
are 3.0–12.2 % and 1.8–11.3 %, respectively, while in
women after surgical treatment of cancer of the vulva, the
percentage of wound infections is even greater and
amounts to 21–39 % [1–5, 7, 8, 10–13].
In most cases, microorganisms responsible for the in-
fections of obstetric and gynecological postoperative
wounds are the patient’s endogenous bacterial flora. Most
commonly isolated strains include: Staphylococcus aureus,
aerobic Gram-negative bacilli (Escherichia coli, Proteus
sp., Klebsiella sp., Enterobacter sp.), Enterococcus sp., b-
hemolyzing streptococci of groups A, B, C and G, anae-
robic bacterial species and Pseudomonas aeruginosa [1, 7,
10, 11]. Methicillin-resistant Staphylococcus aureus
(MRSA) is detected in 2–53 % inoculates from infected
obstetric/gynecological wounds [7, 10, 11]. Fungi, mainly
Candida sp. constitute a rare etiological factor in postop-
erative wound infections in gynecology [7].
Proper management of infected wounds is a multistage
process involving wound debridement, lavasepsis and the
use of local and/or systemic agents (antiseptics, antibi-
otics). In the era of increasing bacterial resistance to an-
tibiotics, topical treatment with antiseptics plays an
important role, as the agents are less selective but allow to
achieve higher therapeutic concentrations within the
wound, particularly in concomitant ischemic conditions.
Antiseptic dressings are an example of such activity;
among these, dressings containing silver are the group of
best documented efficacy.
Antiseptic properties of silver in the treatment of wound
infections were already known in the ancient times. Today,
silver dressings are a novel method for topical treatment of
infected and difficult-to-heal wounds. This is mostly due to
the silver’s broad spectrum of antimicrobial action against
both fungi and bacteria including MRSA or vancomycin-
resistant enterococci (VRE) [20, 71, 73–77]. Combined
with relatively low toxicity, aforementioned properties
make silver a very valuable tool for fighting pathogens
responsible for infections of wounds after iatrogenic
activities.
The mechanisms of silver action involve inhibition of
the cellular respiration, binding of nucleic acids and
causing their denaturation, inhibiting cell replication and
altering the permeability of microbial cell membranes [20,
71, 73, 74, 78]. This is achieved by means of reactions of
the silver ions with proteins, DNA or RNA and negatively
charged chloride ions inside pathogens cells. An adverse
side of this interaction is the inactivation of highly reactive
and positively charged silver ions (Ag?) by chlorides and
various anionic complexes present in the wound bed. As a
result, a rapid drop in the concentration of an active form of
silver that might effectively inhibit the growth of mi-
croorganisms responsible for the infection occurs within
the wound. According to the literature data, concentrations
of silver associated with the highest bactericidal efficacy as
measured by the 3-log reduction in the bacterial counts
should exceed 30–40 mg/l [20, 71, 73]. Therefore, silver-
based treatment of infected wounds requires that the
dressings provide appropriate concentrations of Ag ions in
the wound bed and maintain these concentrations for pos-
sibly the longest time, thus ensuring adequate activity and
preventing resistance.
For nearly four decades of their use, silver nitrate and
silver sulfadiazine became gold standards in the silver-
based treatment of wound infections [71]. Both products
contain positively charged Ag ions in high concentrations
(0.5 % silver nitrate solution—3176 mg/l; 1 % silver sul-
fadiazine—3025 mg/l) [20, 71]. Although, concentration
values markedly exceed the recommended levels of
30–40 mg/l, due to the presence of Ag?, both drugs are
characterized by low residual activity [20, 71, 73].
Achieving appropriate antimicrobial activity requires,
therefore, frequent drug applications into the wound re-
gion—for silver sulfadiazine, it is recommended to change
the dressing twice a day while for silver nitrate, dressings
should be changed 12 times during each 24 h [20, 71, 73,
74].
An innovation in the silver-based therapy of infected
wounds—nanocrystalline silver dressings were introduced
into clinical use in the late 1990s. The novelty of these
dressings as compared to the dressings discussed above
consists in releasing both positively charged Ag ions and
uncharged Ag (Ag0) forms [20, 71, 73–75]. Since un-
charged silver is less prone to react with anionic com-
plexes, it is possible to maintain appropriate concentration
and activity of silver inside the wound for longer periods.
As the reserves of ionic silver are depleted, additional
amounts of Ag0 and Ag? ions are released from the
dressing, ensuring continuous and steady supply of active
silver [73]. The clinical implication of these properties is
the ability to change the dressing less frequently, resulting
in the treatment being more comfortable to the patient and
protecting the wound from injuries that might occur upon
the dressing change [20, 71, 73, 74]. Contrary to other
types of dressings where silver is added in the form of a
solution, cream, ointment or an additional dressing layer,
incorporation of silver nanocrystals with the diameters of
\20 nm into the dressing facilitates accumulation of
larger quantities of silver within a small volume. In
practice this allows to achieve high initial concentration
of silver within the wound. In case of nanocrystalline
silver dressings, this concentration is 70–100 mg/l and
may be maintained at this level for up to 7 days [20, 71,
73, 75].
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The superiority of nanocrystalline silver over silver ni-
trate and silver sulfadiazine in inhibiting bacterial growth
was demonstrated by Yin et al. [76]. Following inoculation
of dressings with an aliquot of bacterial suspension to reach
approximately 107 colony-forming units of S. aureus, re-
searchers demonstrated that the use of nanocrystalline sil-
ver was able to reduce the bacterial counts to less than 102
cells after 1 h application. In case of silver nitrate and
silver sulfadiazine, similar results were obtained after 4 and
6 h, respectively. Study conducted in 1998 by Wright et al.
evaluated bactericidal effects of silver nitrate, silver sul-
fadiazine and nanocrystalline silver against particularly
resistant strains, such as MRSA and VRE [77]. Using a
methodology similar as the previously mentioned investi-
gators, the authors observed a 7-log reduction in MRSA
and VRE counts following 30 min after inoculation when
nanocrystalline silver was used. Reduction of such mag-
nitude could not be observed for dressings containing silver
nitrate or silver sulfadiazine after incubation lasting three
and half hours. Interestingly, both drugs showed only mi-
nor antibacterial activity after 30 min of incubation.
Apart from antimicrobial activity silver delivery sys-
tems, in particular silver nanoparticles present anti-in-
flammatory properties depending on the delivery
technique, available concentration of silver and duration of
release. Reduction in matrix metalloproteinases’ (MMPs)
levels is one of the actions of particular importance as it
was demonstrated that the release of metalloproteinases 2
(MMP-2) and 9 (MMP-9) while being indispensable for
normal healing, may alter its course when present at excess
concentrations by degrading fibronectin, vitronectin and
peptide growth factors [71, 73–75, 78]. The remaining
properties of nanocrystalline silver are responsible for the
down-regulation of inflammatory activity within the wound
area by reducing the TNF-a production and inducing
apoptosis [71, 73–75, 78].
Among the reports published to date on the use of silver-
containing dressings in the treatment of infected postop-
erative wounds, only a few were based on randomized
controlled trials conducted in appropriately large subject
groups with majority being in vitro or case series studies.
Number of reports describing the use of silver in the
treatment of infected and hard-to-heal postsurgical wounds
in obstetrics and gynecology is also limited.
Markowska-Sioma conducted a prospective study to
assess the efficacy of metallic-coated silver dressings in the
treatment of difficult-healing wounds after major gyneco-
logical surgeries [79]. During a 10-month follow-up period,
healing disorders were observed in two patients after
radical vulvectomy and in one patient after abdominal
hysterectomy. Bacteriological examination of wounds re-
vealed the presence of Pseudomonas aeruginosa, Proteus
mirabilis, Streptococcus anhaemoliticus and Enterococcus
faecalis in patients after radical vulvectomy, while a
negative result of culture was obtained for patient after
abdominal hysterectomy. An initial stage of the wound
treatment included autolytic debridement followed by
cleansing of the wound with octenidine before each
dressing change. At the beginning of the treatment silver
dressings were changed every day, and after clinical im-
provement every 2–3 days. On day 14, complete healing of
abdominal hysterectomy wound was observed; radical
vulvectomy wounds took longer to heal, with no times of
complete healing being indicated in the article. In patients’
opinion, the treatment outcomes were positive.
Prophylactic use of silver dressings for the prevention of
surgical site infections in women undergoing cesarean
section was the subject of one full text study. Connery et al.
conducted a retrospective study assessing the efficacy of
dressings consisting of nylon fibers autocatalytically coated
with metallic silver for the prevention of SSIs after the
cesarean section [80]. Among 72 patients in the study, 36
were included in the control group and managed in con-
ventional manner using gauze pads. In the follow-up pe-
riod, postsurgical wound infections were observed in two
patients in the study group and two patients in the control
group. The obtained results could not demonstrate that
silver-impregnated dressings significantly reduced the risk
of SSIs following cesarean section; however, due to the
fact that comorbidities were significantly more common in
the study group, the obtained results might, in the opinion
of investigators, not fully reflect the efficacy of the tested
dressings.
In summary, silver dressings may comprise a useful
tool in the treatment of infected obstetric and gyneco-
logical wounds, although only limited reports suggest
their beneficial effect on the healing process in both
wounds following vulvectomy and wounds after laparo-
tomy as part of hysterectomy or cesarean section proce-
dures. The proven efficacy of silver is largely due to its
low toxicity and broad spectrum of antimicrobial action,
which is particularly important in the era of increasing
bacterial resistance to antibiotics. On the other hand, re-
cently published studies on the prevention of wound in-
fections in patients undergoing cesarean section did not
confirm a higher efficacy of silver dressings compared
with standard dressings while pointing out the high cost
of such treatment. As a consequence, similar as in the
case of NPWT and growth factors, a higher number of
prospective studies must be conducted in an appropriately
large population of women to develop standardized
management methods making use of individual silver
dressings, especially with regard to the particularly
beneficial nanocrystalline silver dressings.
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Summary
Obstetrics and gynecology are examples of surgical disci-
plines where wound healing disorders are one of the most
common complications and the efficacy of standard treat-
ment regimens is not always satisfactory. Chronic, diffi-
cult-to-heal and infected wounds lead to the development
of further, oftentimes serious complications that reduce the
quality of life of the patients, extend hospitalization times
and generate additional treatment costs. Conclusions from
the literature review regarding the use of growth factors,
NPWT and silver dressings suggest that these methods may
play an important role in the management of wound after
invasive obstetric and gynecological procedures. This is
particularly relevant in a group of high-risk patients, e.g.,
obese patients, patients after vulvectomy or previous ra-
diation therapy. The use of novel wound management
methods in above-mentioned patient cohorts may sig-
nificantly improve the final treatment outcomes, reduce
postoperative complications and the related morbidity and
mortality rates, improve the quality of life and reduce costs
due to additional medical procedures. On the other hand,
the non-numerous studies evaluating first attempts to use
these methods in obstetrics and gynecology, mostly non-
randomized and conducted in small populations, do not
permit any definite conclusion regarding their usefulness,
efficacy and cost-effectiveness. Prospective studies on the
use of growth factors, platelet-rich plasma derivatives,
negative pressure wound therapy and silver dressings in the
treatment of chronic, hard-to-heal postsurgical wounds
following obstetric and gynecological interventions are
required.
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